Do the risks of Lynch syndrome-related cancers depend on the parent of origin of the mutation?


Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
07 2020
Historique:
received: 19 11 2019
accepted: 19 02 2020
pubmed: 29 2 2020
medline: 25 5 2021
entrez: 29 2 2020
Statut: ppublish

Résumé

Individuals who carry pathogenic mutations in DNA mismatch repair (MMR) genes have high risks of cancer, and small studies have suggested that these risks depend on the sex of the parent from whom the mutation was inherited. We have conducted the first large study of such a parent-of-origin effect (POE). Our study was based on all MMR gene mutation carriers and their relatives in the Colon Cancer Family Registry, comprising 18,226 people. The POE was estimated as a hazard ratio (HR) using a segregation analysis approach that adjusted for ascertainment. HR = 1 corresponds to no POE and HR > 1 corresponds to higher risks for maternal mutations. For all MMR genes combined, the estimated POE HRs were 1.02 (95% confidence interval (CI) 0.75-1.39, p = 0.9) for male colorectal cancer, 1.12 (95% CI 0.81-1.54, p = 0.5) for female colorectal cancer and 0.84 (95% CI 0.52-1.36, p = 0.5) for endometrial cancer. Separate results for each MMR gene were similar. Therefore, despite being well-powered, our study did not find any evidence that cancer risks for MMR gene mutation carriers depend on the parent-of-origin of the mutation. Based on current evidence, we do not recommend that POEs be incorporated into the clinical guidelines or advice for such carriers.

Identifiants

pubmed: 32107660
doi: 10.1007/s10689-020-00167-4
pii: 10.1007/s10689-020-00167-4
pmc: PMC7410789
mid: NIHMS1611343
doi:

Substances chimiques

DNA-Binding Proteins 0
G-T mismatch-binding protein 0
MLH1 protein, human 0
PMS2 protein, human EC 3.6.1.-
MSH2 protein, human EC 3.6.1.3
Mismatch Repair Endonuclease PMS2 EC 3.6.1.3
MutL Protein Homolog 1 EC 3.6.1.3
MutS Homolog 2 Protein EC 3.6.1.3

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-222

Subventions

Organisme : NCI NIH HHS
ID : R01 CA104132
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000140C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074799
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000035C
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : N01PC35137
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074806
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300012I
Pays : United States
Organisme : NCI NIH HHS
ID : N01PC35142
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000035I
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074799
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074800
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CN067009
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074806
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074800
Pays : United States

Références

Intern Med J. 2015 May;45(5):482-91
pubmed: 25955461
Nat Rev Cancer. 2015 Mar;15(3):181-94
pubmed: 25673086
Genet Epidemiol. 2010 May;34(4):373-81
pubmed: 20397150
Genet Epidemiol. 1988;5(6):471-2
pubmed: 3061869
Dis Colon Rectum. 2002 Sep;45(9):1223-32
pubmed: 12352241
Eur J Hum Genet. 2018 Jul;26(7):1026-1037
pubmed: 29662154
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2331-43
pubmed: 17982118
Aust N Z J Public Health. 2015 Oct;39(5):429-33
pubmed: 26437727
Eur J Med Genet. 2011 Jul-Aug;54(4):e413-8
pubmed: 21540131
Hum Mutat. 2013 Mar;34(3):490-7
pubmed: 23255516
Semin Cell Dev Biol. 2015 Jul;43:117-124
pubmed: 26067997
Genet Med. 2016 Apr;18(4):405-9
pubmed: 26110232
Aust N Z J Public Health. 2015 Oct;39(5):422-8
pubmed: 26437726
Medicine (Baltimore). 2017 Jun;96(22):e7049
pubmed: 28562564
Eur J Cancer Prev. 2015 Jan;24(1):6-15
pubmed: 24722538
PLoS One. 2013 Apr 23;8(4):e61286
pubmed: 23637804
Neurology. 2008 Sep 9;71(11):799-803
pubmed: 18480463
Int J Cancer. 2010 Jul 15;127(2):361-6
pubmed: 19904757
Rural Remote Health. 2011;11(4):1836
pubmed: 22188021
Hum Mutat. 2011 Feb;32(2):207-12
pubmed: 21120946
Am J Hum Genet. 2000 Mar;66(3):1119-31
pubmed: 10712222
Int J Epidemiol. 2018 Apr 1;47(2):387-388i
pubmed: 29490034
PLoS Genet. 2016 Feb 29;12(2):e1005888
pubmed: 26925970
J Clin Oncol. 2008 Dec 10;26(35):5783-8
pubmed: 18809606
Genet Epidemiol. 2001 Jul;21(1):1-18
pubmed: 11443730
Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R138-50
pubmed: 16987877
Clin Nutr. 2017 Jun;36(3):848-852
pubmed: 27206698
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):404-412
pubmed: 27799157
Medicine (Baltimore). 2018 Mar;97(9):e0043
pubmed: 29489655
Neurology. 2009 Aug 25;73(8):602-5
pubmed: 19515994

Auteurs

Shimelis Dejene Gemechu (SD)

Centre for Epidemiology and Biostatistics, University of Melbourne, Parkville, VIC, Australia.

Christine M van Vliet (CM)

Centre for Epidemiology and Biostatistics, University of Melbourne, Parkville, VIC, Australia.

Aung Ko Win (AK)

Centre for Epidemiology and Biostatistics, University of Melbourne, Parkville, VIC, Australia.
Victorian Comprehensive Cancer Centre, University of Melbourne Centre for Cancer Research, Parkville, VIC, Australia.
Genetic Medicine, Royal Melbourne Hospital, Parkville, VIC, Australia.

Jane C Figueiredo (JC)

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Loic Le Marchand (L)

University of Hawaii Cancer Center, Honolulu, Hawaii, USA.

Steven Gallinger (S)

Mount Sinai Hospital, Lunenfeld Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada.

Polly A Newcomb (PA)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
School of Public Health, University of Washington, Seattle, WA, USA.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, University of Melbourne, Parkville, VIC, Australia.

Noralane M Lindor (NM)

Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, AZ, USA.

Mark A Jenkins (MA)

Centre for Epidemiology and Biostatistics, University of Melbourne, Parkville, VIC, Australia.
Victorian Comprehensive Cancer Centre, University of Melbourne Centre for Cancer Research, Parkville, VIC, Australia.

James G Dowty (JG)

Centre for Epidemiology and Biostatistics, University of Melbourne, Parkville, VIC, Australia. jdowty@unimelb.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH